# EDGAR Filing Document

**Accession Number:** 0001938046
**File Stem:** 0000000000-23-001895
**Filing Date:** 2023-2
**Character Count:** 7475
**Document Hash:** e8053b75349f2425b4642eb19925436c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001895.hdr.sgml**: 20230418

**ACCESSION NUMBER**: 0000000000-23-001895

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230224

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MANGOCEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001938046
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **IRS NUMBER:** 873841292
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 15110 DALLAS PKWY, SUITE 600
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75248
- **BUSINESS PHONE:** (833) 626-4679

**MAIL ADDRESS:**
- **STREET 1:** 15110 DALLAS PKWY, SUITE 600
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75248
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-22-026723

## Text-Extract

```

United States securities and exchange commission logo

                              February 24, 2023

       Jacob Cohen
       Chief Executive Officer
       Mangoceuticals, Inc.
       4131 N. Central Expressway, Suite 900
       Dallas, TX 75204

                                                        Re: Mangoceuticals,
Inc.
                                                            Amendment No. 3 to
Registration Statement on Form S-1
                                                            Filed February 21,
2023
                                                            File No. 333-269240

       Dear Jacob Cohen:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our
February 1, 2023 letter.

       Amendment No. 3 to Registration Statement on Form S-1

       Master Services Agreement with Epiq Scripts, page 6

   1.                                                   You state the $15,000
retainer is    to be credited towards future product sales.    Please
                                                        expand the disclosure
here and on page 57 to clarify specifically what the retainer is for,
                                                        e.g. the provision of
pharmacy and related services reported as cost of sales on the
                                                        statement of
operations.
       Managements Discussion and Analysis of Financial Condition and Results
of Operations
       Results of Operations, page 46

   2.                                                   Please provide a
breakdown and explanation of the various expenses that comprise
                                                        your general and
administrative costs for each period presented.
 Jacob Cohen
Mangoceuticals, Inc.
February 24, 2023
Page 2
3.    Please disclosure the nature of cost of revenues and how the amounts are
determined in
      transactions with related parties.
Audited Financial Statements
Statements of Operations, page F-5

4.    Please revise to reflect amounts related to transactions with related
parties as appropriate.
Statements of Cash Flows, page F-7

5.    Please revise to correct the cash flow from financing activities section.
The (25,070) on
      the fourth line appears to be erroneous.
       You may contact Ibolya Ignat at 202-551-3636 or Terence O'Brien at
202-551-3355 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Jimmy McNamara at 202-551-7349 or Joe McCann at 202-551-6262 with any
other
questions.

                                                             Sincerely,

FirstName LastNameJacob Cohen                                Division of
Corporation Finance
                                                             Office of
Industrial Applications and
Comapany NameMangoceuticals, Inc.
                                                             Services
February 24, 2023 Page 2
cc:       David Loev
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

CORPORATION FINANCE

# UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 24, 2023

Jacob Cohen  
Chief Executive Officer  
Mangoceuticals, Inc.  
4131 N. Central Expressway, Suite 900  
Dallas, TX 75204

**Re: Mangoceuticals, Inc.**  
**Amendment No. 3 to Registration Statement on Form S-1**  
**Filed February 21, 2023**  
**File No. 333-269240**

Dear Jacob Cohen:

We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our February 1, 2023 letter.

# Amendment No. 3 to Registration Statement on Form S-1

# Master Services Agreement with Epiq Scripts, page 6

1. You state the $15,000 retainer is “to be credited towards future product sales.” Please expand the disclosure here and on page 57 to clarify specifically what the retainer is for, e.g. the provision of pharmacy and related services reported as cost of sales on the statement of operations.

# Managements Discussion and Analysis of Financial Condition and Results of Operations  
Results of Operations, page 46

2. Please provide a breakdown and explanation of the various expenses that comprise your general and administrative costs for each period presented.

Jacob Cohen
Mangoceuticals, Inc.
February 24, 2023
Page 2

3. Please disclosure the nature of cost of revenues and how the amounts are determined in transactions with related parties.

Audited Financial Statements

Statements of Operations, page F-5

4. Please revise to reflect amounts related to transactions with related parties as appropriate.

Statements of Cash Flows, page F-7

5. Please revise to correct the cash flow from financing activities section. The (25,070) on the fourth line appears to be erroneous.

You may contact Ibolya Ignat at 202-551-3636 or Terence O'Brien at 202-551-3355 if you have questions regarding comments on the financial statements and related matters. Please contact Jimmy McNamara at 202-551-7349 or Joe McCann at 202-551-6262 with any other questions.

Sincerely,

Division of Corporation Finance
Office of Industrial Applications and
Services

cc: David Loev